A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: Background and methodology of the MONITOR-CKD5 study

Loreto Gesualdo, Gérard London, Matthew Turner, Christopher Lee, Karen MacDonald, David Goldsmith, Adrian Covic, Philippe Zaoui, Christian Combe, Johannes Mann, Frank Dellanna, Michael Muenzberg, Ivo Abraham

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Prior longitudinal observational studies have examined the practice patterns and outcomes of anaemia management, including the use of erythropoiesis-stimulating agents (ESAs). Several dimensions of effectiveness remain unaddressed; especially considering the revised ESA label (target Hb levels between 10 and 12 g/dL), the recently published TREAT study, and the European approval of the first ESA biosimilar (HX575). Anecdotal evidence suggests that patient outcomes are influenced by physician-related variables and whether anaemia management is congruent with practice guidelines, but this has not been studied systematically. MONITOR-CKD5 is an international, prospective, observational, pharmacoepidemiological study evaluating the multi-level factors and outcomes of treatment with HX575 for renal anaemia in haemodialysis patients. Driven by a novel, integrated, multi-focal framework for post-approval observational studies, it examines determinants of response at both the patient and the physician level; integrates an advocated statistical methodology here to fore used mainly in the social and behavioural sciences; assesses factors potentially predictive of a poor treatment response; and evaluates the extent to which treatment is congruent with evidence-based guidelines, good practice evidence, and the revised ESA label. This pan-European study will recruit at least 1,000 patients from a minimum of 75 centres, and follow them for up to 24 months following initiation of anaemia management with biosimilar epoetin alfa. MONITOR-CKD5 will not only study the core issues addressed by prior observational studies but also aims to take knowledge discovery a step further by assessing outcomes across varying cohorts of patients, and examining the impact of evidence-based practice on clinical outcomes, differentiating, in the process, between physician-level and patient-level determinants.

Original languageEnglish (US)
Pages (from-to)389-399
Number of pages11
JournalInternal and Emergency Medicine
Volume8
Issue number5
DOIs
StatePublished - Aug 2013
Externally publishedYes

Fingerprint

Epoetin Alfa
Biosimilar Pharmaceuticals
Hematinics
Renal Dialysis
Anemia
Kidney
Observational Studies
Physicians
Practice Guidelines
Behavioral Sciences
Social Sciences
Evidence-Based Practice
Longitudinal Studies

Keywords

  • Biosimilar
  • Erythropoietin
  • Haemodialysis
  • Pharmacoepidemiology
  • Renal anaemia

ASJC Scopus subject areas

  • Emergency Medicine
  • Internal Medicine

Cite this

A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients : Background and methodology of the MONITOR-CKD5 study. / Gesualdo, Loreto; London, Gérard; Turner, Matthew; Lee, Christopher; MacDonald, Karen; Goldsmith, David; Covic, Adrian; Zaoui, Philippe; Combe, Christian; Mann, Johannes; Dellanna, Frank; Muenzberg, Michael; Abraham, Ivo.

In: Internal and Emergency Medicine, Vol. 8, No. 5, 08.2013, p. 389-399.

Research output: Contribution to journalArticle

Gesualdo, Loreto ; London, Gérard ; Turner, Matthew ; Lee, Christopher ; MacDonald, Karen ; Goldsmith, David ; Covic, Adrian ; Zaoui, Philippe ; Combe, Christian ; Mann, Johannes ; Dellanna, Frank ; Muenzberg, Michael ; Abraham, Ivo. / A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients : Background and methodology of the MONITOR-CKD5 study. In: Internal and Emergency Medicine. 2013 ; Vol. 8, No. 5. pp. 389-399.
@article{bfe539b1f66e47c19aa41c1edc2ab752,
title = "A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: Background and methodology of the MONITOR-CKD5 study",
abstract = "Prior longitudinal observational studies have examined the practice patterns and outcomes of anaemia management, including the use of erythropoiesis-stimulating agents (ESAs). Several dimensions of effectiveness remain unaddressed; especially considering the revised ESA label (target Hb levels between 10 and 12 g/dL), the recently published TREAT study, and the European approval of the first ESA biosimilar (HX575). Anecdotal evidence suggests that patient outcomes are influenced by physician-related variables and whether anaemia management is congruent with practice guidelines, but this has not been studied systematically. MONITOR-CKD5 is an international, prospective, observational, pharmacoepidemiological study evaluating the multi-level factors and outcomes of treatment with HX575 for renal anaemia in haemodialysis patients. Driven by a novel, integrated, multi-focal framework for post-approval observational studies, it examines determinants of response at both the patient and the physician level; integrates an advocated statistical methodology here to fore used mainly in the social and behavioural sciences; assesses factors potentially predictive of a poor treatment response; and evaluates the extent to which treatment is congruent with evidence-based guidelines, good practice evidence, and the revised ESA label. This pan-European study will recruit at least 1,000 patients from a minimum of 75 centres, and follow them for up to 24 months following initiation of anaemia management with biosimilar epoetin alfa. MONITOR-CKD5 will not only study the core issues addressed by prior observational studies but also aims to take knowledge discovery a step further by assessing outcomes across varying cohorts of patients, and examining the impact of evidence-based practice on clinical outcomes, differentiating, in the process, between physician-level and patient-level determinants.",
keywords = "Biosimilar, Erythropoietin, Haemodialysis, Pharmacoepidemiology, Renal anaemia",
author = "Loreto Gesualdo and G{\'e}rard London and Matthew Turner and Christopher Lee and Karen MacDonald and David Goldsmith and Adrian Covic and Philippe Zaoui and Christian Combe and Johannes Mann and Frank Dellanna and Michael Muenzberg and Ivo Abraham",
year = "2013",
month = "8",
doi = "10.1007/s11739-011-0622-7",
language = "English (US)",
volume = "8",
pages = "389--399",
journal = "Internal and Emergency Medicine",
issn = "1828-0447",
publisher = "Springer-Verlag Italia",
number = "5",

}

TY - JOUR

T1 - A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients

T2 - Background and methodology of the MONITOR-CKD5 study

AU - Gesualdo, Loreto

AU - London, Gérard

AU - Turner, Matthew

AU - Lee, Christopher

AU - MacDonald, Karen

AU - Goldsmith, David

AU - Covic, Adrian

AU - Zaoui, Philippe

AU - Combe, Christian

AU - Mann, Johannes

AU - Dellanna, Frank

AU - Muenzberg, Michael

AU - Abraham, Ivo

PY - 2013/8

Y1 - 2013/8

N2 - Prior longitudinal observational studies have examined the practice patterns and outcomes of anaemia management, including the use of erythropoiesis-stimulating agents (ESAs). Several dimensions of effectiveness remain unaddressed; especially considering the revised ESA label (target Hb levels between 10 and 12 g/dL), the recently published TREAT study, and the European approval of the first ESA biosimilar (HX575). Anecdotal evidence suggests that patient outcomes are influenced by physician-related variables and whether anaemia management is congruent with practice guidelines, but this has not been studied systematically. MONITOR-CKD5 is an international, prospective, observational, pharmacoepidemiological study evaluating the multi-level factors and outcomes of treatment with HX575 for renal anaemia in haemodialysis patients. Driven by a novel, integrated, multi-focal framework for post-approval observational studies, it examines determinants of response at both the patient and the physician level; integrates an advocated statistical methodology here to fore used mainly in the social and behavioural sciences; assesses factors potentially predictive of a poor treatment response; and evaluates the extent to which treatment is congruent with evidence-based guidelines, good practice evidence, and the revised ESA label. This pan-European study will recruit at least 1,000 patients from a minimum of 75 centres, and follow them for up to 24 months following initiation of anaemia management with biosimilar epoetin alfa. MONITOR-CKD5 will not only study the core issues addressed by prior observational studies but also aims to take knowledge discovery a step further by assessing outcomes across varying cohorts of patients, and examining the impact of evidence-based practice on clinical outcomes, differentiating, in the process, between physician-level and patient-level determinants.

AB - Prior longitudinal observational studies have examined the practice patterns and outcomes of anaemia management, including the use of erythropoiesis-stimulating agents (ESAs). Several dimensions of effectiveness remain unaddressed; especially considering the revised ESA label (target Hb levels between 10 and 12 g/dL), the recently published TREAT study, and the European approval of the first ESA biosimilar (HX575). Anecdotal evidence suggests that patient outcomes are influenced by physician-related variables and whether anaemia management is congruent with practice guidelines, but this has not been studied systematically. MONITOR-CKD5 is an international, prospective, observational, pharmacoepidemiological study evaluating the multi-level factors and outcomes of treatment with HX575 for renal anaemia in haemodialysis patients. Driven by a novel, integrated, multi-focal framework for post-approval observational studies, it examines determinants of response at both the patient and the physician level; integrates an advocated statistical methodology here to fore used mainly in the social and behavioural sciences; assesses factors potentially predictive of a poor treatment response; and evaluates the extent to which treatment is congruent with evidence-based guidelines, good practice evidence, and the revised ESA label. This pan-European study will recruit at least 1,000 patients from a minimum of 75 centres, and follow them for up to 24 months following initiation of anaemia management with biosimilar epoetin alfa. MONITOR-CKD5 will not only study the core issues addressed by prior observational studies but also aims to take knowledge discovery a step further by assessing outcomes across varying cohorts of patients, and examining the impact of evidence-based practice on clinical outcomes, differentiating, in the process, between physician-level and patient-level determinants.

KW - Biosimilar

KW - Erythropoietin

KW - Haemodialysis

KW - Pharmacoepidemiology

KW - Renal anaemia

UR - http://www.scopus.com/inward/record.url?scp=84880421358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880421358&partnerID=8YFLogxK

U2 - 10.1007/s11739-011-0622-7

DO - 10.1007/s11739-011-0622-7

M3 - Article

C2 - 21590439

AN - SCOPUS:84880421358

VL - 8

SP - 389

EP - 399

JO - Internal and Emergency Medicine

JF - Internal and Emergency Medicine

SN - 1828-0447

IS - 5

ER -